arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Karyopharm Therapeutics Inc.

KPTI Health Care Biotechnology: Pharmaceutical Preparations
$0.55
▲ +52.1% Today
as of Oct 22, 16:49 ET
Last 30 days -65.88% Sep 14 → Oct 22
$0.19 $0.64 $1.10 $1.55 $2.01 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$0.44
High
$0.55
Low
$0.42
Volume
$7M
Avg Vol
$924,927
Mkt Cap
$15M
P/E (TTM)
—
Beta
—
52w High
$10.99
52w Low
$0.31
Div Yield
—
Shares Out
$23M

Recent Press Releases & News last 60 days · 5 items

Oct 1 · 20:05 PR PR Newswire
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 11 · 09:37 BioPharma Dive
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
Sep 4 · 08:20 Simply Wall St.
Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates
▸ Show all 5 press releases & news Free account →

KPTI earnings at a glance

Karyopharm Therapeutics Inc. (KPTI) is scheduled to report earnings on Monday, November 2, 2026 — in 10 days. Analysts expect earnings per share of -$1.15, compared with -$3.82 in the same quarter last year (+70%). The options market is pricing a move of about ±67.2% after the report, a range of roughly $0.18 to $0.92 from today's $0.55. Over its last 6 reports the stock rose the next day 3 times and fell 3, moving ±8.8% on average; after the most recent report on Aug 13, 2026 it moved -2.0%. That means options currently expect more movement than KPTI has typically delivered. KPTI beat the consensus EPS estimate in 3 of its last 6 reported quarters. Implied volatility is currently 430%. The share price of $0.55 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$0.31
$11
2% of range
Avg surprise (last 6)
-5.2%
Avg reaction (last 6)
+0.0%
50% positive
Latest IV / EM
430%
EM ±67.2% · $1 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-4.85$-3.71$-2.57$-1.43$-0.29 Actual $-0.30Actual $-0.29Actual $-0.30Actual $-4.85Actual $-2.97Actual $-3.85Actual $-2.77Est $-4.21Actual $-4.32Est $-3.80Actual $-3.82Est $-3.30Actual $-2.23Est $-2.26Actual $-1.24Est $-1.45Actual $-2.32Est $-1.53 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-67M$-39M$-10M$18M$46M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Aug 13, 2026Jun/2026 $-2.32 $-1.53 -51.6% +64.6% -2.0% earnings
Thu May 14, 2026Mar/2026 $-1.24 $-1.45 +14.5% +55.2% +0.6% earnings
Thu Feb 12, 20268K 2026-02-12 $-2.23 $-2.26 +1.3% — +21.3% earnings
Mon Nov 3, 2025Sep/2025 $-3.82 $-3.30 -15.8% — +4.7% earnings
Mon Aug 11, 2025Jun/2025 $-4.32 $-3.80 -13.7% — -4.3% earnings
Mon May 12, 2025Mar/2025 $-2.77 $-4.21 +34.2% — -20.0% earnings
Mon Sep 30, 2024Sep 2024 $-3.85 — — — — financials
Sun Jun 30, 2024Jun 2024 $-2.97 — — — — financials
Sun Mar 31, 2024Mar 2024 $-4.85 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.30 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.29 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.30 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Mon Nov 2, 2026Sep/2026OTHER -$1.15-$3.82 +69.9%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$33M$35M—$44M$38M$30M—$39M
Cost of revenue————————
Gross profit————————
Operating income$-23M$-27M—$-15M$-24M$-33M—$-26M
Net income$-67M$-22M—$-33M$-37M$-23M—$-32M
EPS (diluted)$-2.32$-1.24—$-3.82$-4.32$-2.77—$-3.85

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$55M$91M$61M$38M$39M$39M$62M$73M
Inventory$4M$4M$4M$4M$5M$5M$5M$5M
Total current assets$106M$126M$103M$90M$98M$120M$156M$185M
Total assets$111M$131M$108M$96M$105M$128M$164M$189M
Long-term debt————————
Total liabilities$441M$397M$401M$365M$344M$334M$350M$349M
Total equity$-330M$-266M$-293M$-269M$-239M$-206M$-186M$-160M

Implied volatility — last 90 days

50%293%535%777%1019% Jun 07 — IV 87% · EM ±12.1%Jun 09 — IV 289% · EM ±36.2%Jun 10 — IV 211% · EM ±25.0%Jun 11 — IV 71% · EM ±7.9%Jun 12 — IV 327% · EM ±33.4%Jun 15 — IV 315% · EM ±22.8%Jun 16 — IV 242% · EM ±14.3%Jun 17 — IV 599% · EM ±25.0%Jun 19 — IV 130% · EM ±28.8%Jun 22 — IV 196% · EM ±40.8%Jun 23 — IV 180% · EM ±36.8%Jun 24 — IV 150% · EM ±30.0%Jun 25 — IV 181% · EM ±35.4%Jun 26 — IV 205% · EM ±39.2%Jun 29 — IV 210% · EM ±37.2%Jun 30 — IV 229% · EM ±39.4%Jul 01 — IV 282% · EM ±47.1%Jul 02 — IV 285% · EM ±46.1%Jul 03 — IV 295% · EM ±46.1%Jul 06 — IV 341% · EM ±47.3%Jul 07 — IV 290% · EM ±38.3%Jul 08 — IV 326% · EM ±40.9%Jul 09 — IV 270% · EM ±31.9%Jul 10 — IV 319% · EM ±35.3%Jul 13 — IV 363% · EM ±30.3%Jul 14 — IV 304% · EM ±22.0%Jul 15 — IV 386% · EM ±22.8%Jul 16 — IV 434% · EM ±18.1%Jul 20 — IV 244% · EM ±57.6%Jul 21 — IV 267% · EM ±62.0%Jul 22 — IV 264% · EM ±60.4%Jul 23 — IV 320% · EM ±72.0%Jul 24 — IV 327% · EM ±72.2%Jul 27 — IV 306% · EM ±63.8%Jul 28 — IV 340% · EM ±69.5%Jul 29 — IV 366% · EM ±73.3%Jul 30 — IV 330% · EM ±64.6%Jul 31 — IV 237% · EM ±45.3%Aug 03 — IV 192% · EM ±34.1%Aug 04 — IV 250% · EM ±43.0%Aug 05 — IV 266% · EM ±44.5%Aug 06 — IV 480% · EM ±77.6%Aug 07 — IV 62% · EM ±9.6%Aug 10 — IV 276% · EM ±38.3%Aug 11 — IV 108% · EM ±14.3%Aug 13 — IV 296% · EM ±35.0%Aug 14 — IV 515% · EM ±56.9%Aug 17 — IV 874% · EM ±73.0%Aug 18 — IV 1020% · EM ±73.8%Aug 24 — IV 52% · EM ±10.8%Aug 25 — IV 64% · EM ±13.0%Aug 26 — IV 51% · EM ±10.2%Aug 27 — IV 184% · EM ±36.1%Aug 28 — IV 251% · EM ±48.1%Aug 31 — IV 68% · EM ±12.0%Sep 01 — IV 510% · EM ±87.8%Sep 02 — IV 100% · EM ±16.7%Sep 03 — IV 157% · EM ±25.4%Sep 04 — IV 286% · EM ±44.7%Sep 07 — IV 323% · EM ±44.7%Sep 09 — IV 590% · EM ±74.0%Sep 10 — IV 263% · EM ±31.1%Sep 11 — IV 619% · EM ±68.4%Sep 14 — IV 374% · EM ±31.2%Sep 15 — IV 628% · EM ±45.5%Sep 16 — IV 755% · EM ±44.6%Sep 21 — IV 245% · EM ±51.1%Sep 23 — IV 328% · EM ±65.7%Sep 29 — IV 71% · EM ±12.2%Oct 01 — IV 422% · EM ±68.2%Oct 02 — IV 430% · EM ±67.2%

Sector peers

LEXX
Lexaria Bioscience Corp.
$14M $2.99+12.8%
ALLR
Allarity Therapeutics, Inc.
$17M $0.85-3.4%
DARE
Dare Bioscience, Inc.
$17M $0.65-5.4%
RKTO
Rocket One Inc.
$17M $0.53+0.3%
BLRX
BioLineRx Ltd.
$12M $2.06-6.7%
ASBP
Aspire-Lakewood Holdings, Inc.
$11M $8.90+2.1%

KPTI earnings FAQ

When is KPTI's next earnings date?

Karyopharm Therapeutics Inc. is expected to report on November 2, 2026.

What is KPTI's expected move for earnings?

Options currently price a move of about ±67.2%, or $0.37 per share either way from $0.55.

How does KPTI stock usually react to earnings?

Across the last 6 reports the average next-day move was ±8.8%, up 3 times and down 3 times.

What EPS are analysts expecting from Karyopharm Therapeutics Inc.?

The consensus estimate is -$1.15 per share, versus -$3.82 a year ago.

What is KPTI's implied volatility?

KPTI's at-the-money implied volatility is about 430% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in